Immunovant (IMVT) Current Leases (2020 - 2026)
Immunovant's (IMVT) quarterly Current Leases came in at $72000.0 in Q1 2026, down 26.53% YoY from $98000.0 in Q1 2025, and down 26.53% on a QoQ basis from $98000.0 in Q1 2025.
Immunovant (IMVT) Current Leases (2020 - 2026) Analysis & Trends
Immunovant (IMVT) has 7 years of Current Leases data on file, last reported at $72000.0 in Q1 2026.
- Quarterly Current Leases fell 26.53% year-over-year to $72000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72000.0 (down 26.53% YoY) and the FY2026 annual result came in at $72000.0, down 26.53% from the prior year.
- Current Leases eased to $72000.0 in Q1 2026, from $98000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.2 million in Q4 2022 to a low of $23000.0 in Q4 2024.
- A 5-year average of $582785.7 and a median of $460000.0 in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases climbed 11.68% — and 2024, when it tumbled 92.49%.
- Tracing IMVT's Current Leases over 5 years: stood at $1.2 million in 2022, then sank by 74.61% to $306000.0 in 2023, then sank by 92.48% to $23000.0 in 2024, then soared by 326.09% to $98000.0 in 2025, then retreated by 26.53% to $72000.0 in 2026.
- The last three Current Leases figures came in at $72000.0 (Q1 2026), $98000.0 (Q1 2025), and $23000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Dec 31, 2023 | 306,000.00 |
| Sep 30, 2023 | 614,000.00 |
| Jun 30, 2023 | 919,000.00 |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.17 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.08 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.18 Mn |
| Dec 31, 2020 | 1.10 Mn |
| Sep 30, 2020 | 1.10 Mn |